A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations

Development of a Method for Multisensory Stripping Voltammetry in the Analysis of Medical Preparations

For the effective dosage of newly developed ophthalmic drugs, an assessment of the dynamics of their concentration in lacrimal fluid over time is required. To express the detection and identification of drugs, new methods are needed that must meet numerous requirements, not the least of which are selectivity, speed, the absence of false-negative results, and cost-effectiveness. The possibility of identifying anesthetics (sevoflurane) in lacrimal fluid has been studied using a new electrochemical method of multisensory inversion voltammetry in the electronic tongue and electronic nose format. The measurements were performed on a planar electrode, which is a three-electrode structure. The solution of the test system consisted of 0.05 M KCl, which contained the metal cations Zn2+, Cd2+, Pb2+, Co2+, and Hg2+ at a concentration of 5 × 10-5 M. It is shown that this method is effective for the determination of anesthetics, and the dynamics of changes in their concentration over time are examined. This study aimed to research the behavioral pharmacokinetics in the lacrimal fluid of the opioid drug sevoflurane in pediatric ophthalmology using multisensory stripping voltammetry in patients during strabismus correction surgery. The dynamics of changes in their concentrations over time were examined. After the instillation of the anesthetics in patients, their concentrations in the tear fluid remained unchanged within 10 min. The list of organic substances that can be determined by multisensory stripping voltammetry has been extended. The class of organic substances determined by the method of multisensory inversion voltammetry has been expanded.

SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer

INTRODUCTION

Patients ≥ 70 years old constitute 40% of patients with advanced gastric cancer (GC). Ramucirumab plus Paclitaxel is a therapeutic option validated in the second-line treatment of advanced GC, but as older patients are at higher risk of severe toxicity, due to comorbidities and/or frailty, we aimed to evaluate second-line Ramucirumab alone or combined with Paclitaxel in terms of overall survival (OS) and quality of life (QoL) in patients ≥ 70 years-old with advanced GC.

METHODS

In this multicenter, randomized, open-label, non-comparative, prospective phase II clinical trial, the main inclusion criteria are: patients ≥ 70 years old, with advanced GC having progressed after first-line chemotherapy or in the six months following the last administration of adjuvant chemotherapy, with WHO performance status <2. They are randomized to receive either ramucirumab alone (arm A) or ramucirumab plus Paclitaxel (arm B). The primary endpoint is 6-month OS and QoL evaluated with the EORTC QLQ-ELD14 questionnaire. The secondary endpoints include other parameters of QoL, time to definitive deterioration (TTDD) in QoL and TTDD in autonomy, treatment toxicities, other parameters of survival and disease control, identification of geriatric and nutritional prognostic scores and predictive factors of treatment safety and efficacy. OS of 60% is expected at 6 months (H0:40%). Using a Simon-minimax design, with one-sided α risk of 2% and 80% power for OS, and considering 5% lost to follow-up, it is necessary to randomize 56 patients in each arm.

PERSPECTIVES

As older patients are at higher risk of chemotherapy toxicity, ramucirumab alone could be an interesting alternative to Paclitaxel plus ramucirumab, as a second-line therapy for patients ≥ 70 years old with advanced GC, and needs to be evaluated.